Pfizer and Adaptive entered two non-exclusive immune receptor licensing agreements. Adaptive will lead target discovery to identify disease-specific RA TCRs; Pfizer responsible for development/commercialization. Total deal up to ~$890M in upfront, data delivery, development, commercial and sales milestones.